Effect of systolic blood pressure status on coronary inflammation and high-risk plaque characteristics

doi:10.4239/wjd.v16.i4.102751

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (0)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-5) series, Tables (1-8) series.

Item

Count

PDF

HTML

Figures (1-5)

Tables (1-8)

Sum=0

Apr 15, 2025 (publication date) through Feb 28, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Diabetes. Apr 15, 2025; 16(4): 102751
Published online Apr 15, 2025. doi: 10.4239/wjd.v16.i4.102751

Table 2 Clinical baseline characteristics of the normotension group, controlled systolic blood pressure group, and uncontrolled systolic blood pressure group

Variables	Normotension group, n = 213	Controlled SBP group, n = 313	Uncontrolled SBP group, n = 355	P value
Baseline characteristic
Age (years)	58.15 ± 9.24	62.80 ± 10.07^a	63.16 ± 11.16^a	< 0.001
Male sex	90 (42.3)	156 (49.8)^a	201 (56.6)^a	0.00
Body mass index (kg/m²)	23.71 ± 3.16	24.39 ± 3.40	24.43 ± 3.78^a	0.030
Smoking	33 (15.5)	51 (16.3)	72 (20.3)	0.208
Dyslipidemia	94 (44.1)	121 (38.7)	157(44.2)	0.379
Systolic pressure (mmHg)	118 ± 9	125 ± 8^a	153 ± 15^a^,^b	< 0.001
Diastolic pressure (mmHg)	73 ± 8	76 ± 10^a	87 ± 13^a^,^b	< 0.001
Laboratory findings
Fast glucose (mmol/L)	6.45 ± 2.48	7.31 ± 4.10	7.45 ± 3.69	0.065
HbA1c (%)	7.37 ± 2.36	6.76 ± 1.84	7.11 ± 1.96^a^,^b	0.040
Triglyceride (mmol/L)	1.36 (0.91, 1.82)	1.43 (0.83, 2.03)	1.50 (0.62, 2.38)^a	0.027
Total cholesterol (mmol/L)	4.41 ± 1.20	4.61 ± 1.24	4.80 ± 1.05^a	0.006
HDL-cholesterol (mmol/L)	1.25 ± 0.36	1.21 ± 0.35	1.22 ± 0.38	0.530
LDL-cholesterol (mmol/L)	2.59 ± 0.85	2.73 ± 1.00^a	2.99 ± 0.90^a	< 0.001
Lipid - lowering medication
Statin	127 (59.6)	207 (66.1)	260 (73.2)^a^,^b	0.001
Hypertension treatment
ACEI/ARB	-	105 (33.5)	106 (29.9)	0.387
Beta - blocker	-	51 (16.3)	50 (14.1)	0.261
Diuretics	-	26 (8.3)	21 (5.9)	0.394
Calcium channel blocker	-	167 (53.4)	162 (45.6)	0.099
Diabetes treatment
Oral	70 (32.9)	100 (31.9)	124 (34.9)	0.762
Insulin	15 (7.0)	27 (8.6)	31 (8.7)	0.647
Tube voltage of CT acquisition				0.001
100	139 (65.3)	174 (55.6)	161 (45.4)
120	71 (33.4)	131 (41.9)	171 (48.2)
140	3 (1.4)	8 (2.6)	23 (6.5)

^aP < 0.005 vs the normotension group.

^bP < 0.005 vs the controlled group.

Data are showed as means ± SD, median (25^th and 75^th percentile), or n (%). SBP: Systolic blood pressure; HbA1c: Glycated hemoglobin; LDL: Low-density lipoprotein; HDL: High-density lipoprotein; ARB/ACEI: Angiotensin receptor blockers/angiotensin-converting enzyme inhibitors; CT: Computed tomography.

Citation: Jiang CP, Liu YK, Cheng PP, Dong Y, Wang X, Wu FY, Xia YX, Wang PY, Xu XY. Effect of systolic blood pressure status on coronary inflammation and high-risk plaque characteristics. World J Diabetes 2025; 16(4): 102751
URL: https://www.wjgnet.com/1948-9358/full/v16/i4/102751.htm
DOI: https://dx.doi.org/10.4239/wjd.v16.i4.102751